General FAQs
1. When was Protherics formed?
Protherics was formed in September 1999 through the merger of Proteus International PLC and Therapeutic Antibodies Inc.
2. What is the ticker symbol for Protherics and on what exchange do the shares trade?
Please see our Shareholder Information section
3. How many shares does Protherics' have in issue?
Please see our Shareholder Information section
4. How can I get a copy of Protherics' Annual Report?
You can view a copy of the latest Financial Report by clicking on this link or if you require it in hard copy you can request it from the Financial Times Annual Reports Service.
5. When does Protherics' report its financial results?
The Protherics financial year end is the 31 March and results are usually reported at the beginning of June. The half year end is 30 September and the interim statement is usually published at the end of November or beginning of December.
6. Who do I contact if I have a query about my share certificate?
Please contact our registrars:
Capita Registrars
Northern House
Woodsome Park
Fenay Bridge
Huddersfield West
Yorkshire HD8 0LA UK
Email: shareholder.services@capitaregistrars.com
Tel: 0870 162 3131 (if calling from overseas +44 (0)20 8639 2300)
Fax: 020 8639 2342 (if calling from overseas +44 (0)20 8639 2342)
7. How can I buy and sell Protherics' shares?
You can deal in Protherics' shares through any Stockbroker who trades shares in companies listed on the London Stock Exchange.
8. I hold Protherics PLC 6% unsecured convertible loan notes 2010 which were issued following the acquisition of Enact Pharma Plc. Are the loan notes now convertible into ordinary shares in Protherics PLC?
Your loan notes are convertible into ordinary shares in Protherics PLC at a price of 25p per share. If you wish to convert your loan notes, you should contact the Company’s Registrars at the address above and they will explain the process to you.
9. If I have an old share certificate in the name of Proteus International PLC, is it still valid?
Your share certificate is still valid and will be accepted in the normal way.
For product specific queries please also look at the relevant product page.
Please contact our Investor Relations team if you have any further questions.